Rusfertide Acetate Patent Expiration

Rusfertide Acetate was first introduced by Takeda Pharmaceuticals America Inc in its drug Mimrylo on Aug 28, 2026.


Rusfertide Acetate Patents

Given below is the list of patents protecting Rusfertide Acetate, along with the drug name that holds that patent and the company name owning that drug.

Filter patents by

NEW
Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Mimrylo US10030061 Hepcidin Analogues And Uses Thereof Mar 17, 2034 Takeda Pharms Am
Mimrylo US10442846 Hepcidin Analogues And Uses Thereof Mar 17, 2034 Takeda Pharms Am
Mimrylo US10501515 Hepcidin Analogues And Uses Thereof Mar 17, 2034 Takeda Pharms Am
Mimrylo US11807674 Hepcidin Analogues And Uses Thereof Mar 17, 2034 Takeda Pharms Am
Mimrylo US12269856 Hepcidin Analogues And Uses Thereof Mar 17, 2034 Takeda Pharms Am
Mimrylo US9822157 Hepcidin Analogues And Uses Thereof Mar 17, 2034 Takeda Pharms Am



Rusfertide Acetate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Rusfertide Acetate Generic API Manufacturers

Given below is the list of companies who have filed for Rusfertide Acetate generic, along with the locations of their manufacturing plants worldwide.